Barclays analyst Matt Miksic raised the firm’s price target on Boston Scientific (BSX) to $125 from $118 and keeps an Overweight rating on the shares. The firm says ADVANTAGE-AF’s solid results for the use of Farawave and Farapoint in persistent atrial fibrillation should support FDA approval later this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific says second phase of ADVANTAGE AF study met primary endpoints
- Boston Scientific price target raised to $117 from $113 at Truist
- Boston Scientific price target raised to $120 from $116 at RBC Capital
- Boston Scientific price target lowered to $121 from $122 at Raymond James
- Boston Scientific price target raised to $120 from $115 at Baird